small molecules have been by far the most successful class of CNS therapeutics.On one hand, common problems, such as when CNS-to-blood transporters prevent their accumulation in the brain, challenge their wider development.
No takes yet. Share an insight, caveat, or question.
Banks et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: